Last reviewed · How we verify

NCT06570044

Evaluation of PerioMonitor for Detection of Oral Inflammatory (OI) in Human Subjects in Medical Practice

Completed NA Last updated 21 May 2025
What this trial tests

NA trial testing PerioMonitor in Oral Inflammation in 86 participants. Completed in 1 May 2025.

Timeline
30 July 2024
Primary endpoint
30 January 2025
1 May 2025

Quick facts

Lead sponsorOral Science International Inc.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment86
Start date30 July 2024
Primary completion30 January 2025
Estimated completion1 May 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Oral Science International Inc.

Who can join

18 and older, any sex, with Oral Inflammation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate the usability of PerioMonitor™ in a medical clinic environment and to evaluate the effectiveness of a referral system from physicians to dentists for patients identified with high oral inflammation. PerioMonitor™ is an In Vitro Diagnostic (IVD) device intended as an aid in the detection of oral inflammation in individuals of 18 years and older. This test is intended for use at point-of-care (POC) sites by health care professionals (e.g., physicians, nurses, medical assistants, dentists, dental hygienists, and dental assistants).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Oral Science International Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06570044.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing